AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Supernus Pharmaceuticals Acquires Sage Therapeutics to Strengthen Presence in Neuropsychiatric Conditions
ByAinvest
Thursday, Jul 31, 2025 8:46 am ET1min read
Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics, adding a fourth growth product, ZURZUVAE, and diversifying its revenue base. The acquisition is expected to be accretive in 2026 and brings in collaboration revenue from net sales of ZURZUVAE. Supernus also gains a CNS discovery platform and expects cost synergies of up to $200 million annually. The acquisition strengthens its presence in neuropsychiatric conditions and positions it for significant future growth.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet